COAPT: Mortality or Rehospitalization Remains Significantly Lower for MitraClip over Optimal Medical Therapy at 3 Years
SAN FRANCISCO – MitraClip’s lower rates of mortality and heart failure rehospitalization over optimal medical therapy remained significant at 3 years, according to the latest COAPT trial results presented Saturday at Transcatheter Cardiovascular Therapeutics 2019.